Add-on Acquisition • Life Science

Abiogen Pharma Acquires EffRx

On May 29, 2023, Abiogen Pharma acquired life science company EffRx

Acquisition Context
  • This is Abiogen Pharma’s 1st transaction in the Life Science sector.
  • This is Abiogen Pharma’s 1st transaction in Switzerland.

Explore All 3110 Add-on Acquisition Life Science Deals - Search the Database Free


M&A Deal Summary

Date May 29, 2023
Target EffRx
Sector Life Science
Buyer(s) Abiogen Pharma
Deal Type Add-on Acquisition

Target Company

EffRx

Freienbach, Switzerland
EffRx develops and commercializes drugs, targeted in particular to musculoskeletal and rare diseases. The company's product range includes buffered soluble alendronate, a key agent from the class of bisphosphonates used in the treatment of osteoporosis. It licenses and distributes this drug under license agreements in 29 European and non-European countries. EffRx was founded in 2010 and is based in Freienbach, Switzerland.
Explore More Deals

Browse All 215,158 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Buyer Overview 1

Buyer

Abiogen Pharma

Pisa, Italy

Category Company
Founded 1997
Sector Life Science
DESCRIPTION

Abiogen Pharma research and development, manufacturing of pharmaceuticals with its own brand or under third-party contracts, and marketing of own and licensed drugs. Abiogen Pharma was founded in 1997 and is based in Pisa, Italy.


Deal Context for Buyer #
Overall 2 of 2
Sector: Life Science 1 of 1
Type: Add-on Acquisition 2 of 2
Country: Switzerland 1 of 1
Year: 2023 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-12-08 Altamedics

Koln, Germany

Altamedics distributes pharmaceuticals – namely hospital products – on the domestic and on several international markets, via third-party manufacturing sites and its warehouse and logistics centre in Neunkirchen. Altamedics was founded in 2009 and is based in Koln, Germany.

Buy -